R enal insufficiency is associated with an altered lipoprotein metabolism leading to an atherogenic lipid profile (1) . This dyslipoproteinemia does not appear to be substantially modified by dialysis treatment (2) (3) (4) (5) . However, patients on peritoneal dialysis (PD) seem to have a more disturbed lipid profile than those on hemodialysis (2, (5) (6) (7) (8) (9) (10) (11) (12) (13) .
The aim of this cross-sectional study was to relate PD variables to the lipoprotein profile in patients on long-term PD, in order to identify possible factors underlying the aggravated dyslipoproteinemia in this category of renal patients.
SUBJECTS AND METHODS

PATIENT POPULATION
Twenty-two nondiabetic patients (5 women, 17 men) were studied. To be included in the study, it was required that patients had been on PD treatment for at least 6 months. The average duration of PD was 15.3 months (range 6 -48 months, median 10 months). Nineteen patients had primary renal disease and the remaining patients had vasculitis (n = 2) or amyloidosis (n = 1) as the underlying renal disorder. No patient was on steroid or lipid-lowering treatment. Their mean age at examination was 61 years (range 36 -85, median 59.5 years). Three patients were on automated peritoneal dialysis (APD) and the remaining patients were on standard continuous ambulatory peritoneal dialysis (CAPD) with manual exchanges, using 8 -10 L dialysis fluid each day. The mean total creatinine clearance was 69.7 L/ week/1.73m 2 body surface area (BSA), with an average residual renal function of 2.1 mL/min/1.73m 2 BSA (range 0 -4.6 mL/min/1.73m 2 BSA).
CONTROL GROUP Twenty-two healthy Swedish subjects (5 women, 17 men) with a mean age of 55.2 years (range 46 -75 years) were used as an age-and sex-matched reference group.
M E T H O D S
Blood samples for lipoprotein analyses were drawn from an antecubital vein and collected in EDTA-containing tubes. The samples were taken in the morning after an overnight fast, without interruption of the ordinary dialysis schedule. Plasma samples were preserved using a solution of 0.13% ε-aminocaproic acid and 0.1% thiomerosal. The samples were then shipped by express airfreight in the fresh state to the Lipid and Lipoprotein Laboratory at the Oklahoma Medical Research Foundation for lipid and apolipoprotein (Apo) analyses.
Plasma concentrations of total cholesterol and triglycerides were measured by enzymatic procedures as previously described (14) . High density lipoprotein (HDL)-cholesterol was measured after precipitation of ApoB-containing lipoproteins in whole plasma by heparin-manganese chloride (15) . Very low density lipoprotein (VLDL)-cholesterol, assumed to be one fifth of the plasma triglyceride concentration, and LDL-cholesterol were determined according to the method of Friedewald (16) .
Apolipoprotein analyses were performed by electroimmunoassay (17) (18) (19) (20) . Apolipoprotein C-III in heparin-manganese supernate (ApoC-III HS), that is, in HDL, and heparin-manganese precipitate (ApoC-III HP), that is, in VLDL+LDL, were determined according to a previously described procedure (21) . The ratio between ApoC-III HS and ApoC-III HP is referred to as the ApoC-III ratio. A low ratio indicates less efficient catabolism and removal of triglyceride-rich lipoproteins.
Apoprotein A-containing lipoproteins consist of two major lipoprotein families, LP-A-I and LP-A-I:A-II (1). They were quantified by a modified differential electroimmunoassay (22) . The simple cholesterol-rich LP-B and the complex triglyceride-rich lipoproteins, referred to as LP-B complex (LP-Bc), are the two major groups of ApoB-containing LPs (1) . LP-Bc is the sum of the individual ApoB-containing lipoproteins that, apart from ApoB, also have at least one other type of Apo constituent (1) . Lipoprotein-B and LP-Bc were isolated from plasma by immunoaffinity chromatography on an anti-ApoC-III immunosorber (23) . The retained and unretained fractions were then analyzed separately for ApoB.
Dialysis efficacy and peritoneal properties were analyzed by the peritoneal dialysis capacity (PDC) method (24): 24-hour dialysis fluids were collected and analyzed for urea, creatinine, albumin, and glucose content. The dialysis regimen on the day of measurement included five exchanges with varying dwell times and glucose concentrations. Drained volumes were measured for each dwell; time points for start of emptying and filling were registered, as were glucose concentrations of the bags used. Peritoneal glucose uptake and peritoneal protein losses were measured. Blood samples were drawn for analyses of sodium, urea, creatinine, glucose, and albumin. The collected data are used to describe the peritoneal properties based on the three-pore model and equations with nonlinear flux analysis of the diffusive and convective clearances through these pores. Thus, peritoneal function is described by the PDC parameters, "effective area," "reabsorption rate," and "large-pore flow." The "effective area," or rather the total pore area over the diffusion distance, Ao/Δx, determines the diffusion of small solutes and the ultrafiltration coefficient. The "reabsorption rate" denotes the final reabsorption rate of fluid from the abdominal cavity to blood, when the glucose gradient has dissipated. Finally, the "large-pore flow" determines the protein losses to the dialysis fluid, that is, the plasma protein flux through large pores. Peritoneal creatinine clearance was then predicted for the actual regimen.
Residual renal function (RRF) was calculated as the mean of 24-hour urea and creatinine clearances. Serum albumin was measured by nephelometry.
The examinations of dialysis efficacy and peritoneal properties were done on the day following the lipoprotein analysis in 10 patients. In all but one patient (Patient O), the dialysis assessment was performed within 2.5 months of the lipoprotein analysis. In this patient, the lipoprotein determination was performed 6 months after the PDC examination. 
R E S U L T S
LIPOPROTEIN PROFILE (TABLE 1, FIGURES 1, 2, 3)
The plasma concentrations of triglycerides and total cholesterol were both markedly elevated in the PD patients compared to the healthy controls. Also, VLDLand LDL-cholesterol were significantly elevated, whereas HDL-cholesterol was lower in the patient group.
The Apo pattern of the patients also differed significantly from healthy controls, with lower ApoA-I and ApoA-II and higher ApoB and ApoE plasma concentrations. The plasma level of ApoC-III was twice as high as the normal value. The high ApoC-III levels were primarily due to a marked increase in ApoC-III in heparin-manganese precipitate, that is, in VLDL and LDL. This resulted in a significantly decreased C-III ratio of 0.7 (SD 0.6) in comparison to 1.5 (SD 1.0) in the controls (p < 0.001).
Both the LP-B and LP-Bc plasma concentrations were markedly elevated in the PD patients (by approximately 50% and 100%, respectively). The decrease in ApoA-I was completely due to a reduction in the LP-A-I:A-II level, whereas the LP-A-I did not differ from healthy controls.
As depicted in Figures 1, 2 , and 3, there is a wider interindividual variation in most of the lipoprotein variables in the patients than in the healthy control subjects.
PERITONEAL CHARACTERISTICS (TABLE 2) AND NUTRITIONAL STATUS
The peritoneal characteristics of the patients are shown in Table 2 . There was a great interindividual variability in the patients with respect to peritoneal surface area, absorption rate, and large-pore flow. All patients had a substantial daily protein loss and a nonnegligible caloric uptake. Fifteen of 22 patients had a total creatinine clearance above 60 L/week/ 1.73 m 2 BSA.
The mean body weight (BW) was 72.6 (SD 9.0) kg and the body mass index (BMI) was 24.3 (SD 2.8) kg/m 2 .
There had been no significant change in BW during the 6 months prior to the study [ΔBW = 0.4 (SD 2.8) kg], although there was a wide interindividual variability (range -4 kg to +5.5 kg). Serum albumin levels were slightly lower than normal, with an average of 33.4 (SD 5.1, range 23.5 -41) g/L.
CORRELATIONS BETWEEN PERITONEAL CHARACTERISTICS AND LIPOPROTEIN VARIABLES
The effective peritoneal area was inversely correlated with the plasma concentration of ApoA-II (r = 0.53, p < 0.05), and to serum albumin (r = 0.65, p < 0.01). No other lipoprotein variable correlated with the area parameter.
There were no correlations between the reabsorption rate, large-pore flow, peritoneal protein losses, peritoneal caloric uptake, peritoneal creatinine clearance, or total creatinine clearance, respectively, and any of the lipid or lipoprotein variables.
LP-A-I:A-II and ApoA-II correlated inversely with the duration of PD (r = 0.54, p < 0.01 and r = 0.52, p < 0.05, respectively).
Finally, there were no significant correlations between peritoneal protein losses and serum albumin or protein losses and the area parameter.
DISCUSSION
This study investigated the relationship between PD variables and the lipoprotein profile in patients on long-term PD treatment. The main findings were that the patients had an unfavorable lipid profile, with marked elevations of both cholesterol-rich and triglyceride-rich ApoB-containing lipoproteins, with a concomitant decrease of ApoA-containing lipoproteins, and that the duration of PD therapy seemed to have a negative effect on the dyslipidemia. The study was performed in a group of patients representative of the nondiabetic PD population at our center with respect to renal diagnoses, nutritional parameters, sex distribution, and patient age. In reference to peritoneal characteristics (the PDC variables), "area parameter" was slightly smaller and "reabsorption rate" was somewhat higher (82% and 139% of the reference values, respectively) in the present patient series than in the earlier report from 1995 (24) . Using the peritoneal equilibration test (PET) terminology, most of the patients would be characterized as "low-average" and "high-average" transporters (25) . Most of the patients reached an acceptable level of dialysis efficacy, having a weekly creatinine clearance close to or above 60 L.
The PDC method, which we have used to describe the functional characteristics of the peritoneal membrane and to measure the effects of dialysis, is based on current theories of capillary physiology (24) . The total pore area (Ao/Δx), which determines the diffusive capacity of small solutes, and the large-pore flow, which determines the protein losses, are described as separate entities. This detailed approach is one of the benefits of the PDC when used in clinical research. In the original paper on the PDC method, excellent accuracy was reported when calculated clearance values were compared to actual measured clearances. In addition, the PDC parameters were highly reproducible (24) . Recent publications have validated the PDC test in children (26) , and it has been applied in a Japanese PD population with good results (27) .
As already stated, renal dyslipoproteinemia is reflected in an abnormal Apo profile rather than in elevated plasma lipid levels (1). Therefore, we should also include analyses of Apos and the composition of lipoprotein particles when we try to understand the influence of dialysis treatment on the lipoprotein profile. However, the great majority of studies of lipoproteins in various categories of renal patients have not used methods that directly measure lipoprotein particles. This was done in the present study using immunoaffinity chromatography (22, 23) . These methods have previously been shown to be reliable in patients with various degrees of renal functional impairment (28) . The results of the present study are in accordance with those reported by others -with markedly elevated levels of ApoB-containing lipoproteins and moderately decreased levels of ApoA-containing lipoproteins (4, 5, 7, 8, 10, 12, 13, (29) (30) (31) . The observed increased level of LP-B is not a general finding in advanced renal failure (1), but seems to be particularly pronounced in PD. The levels of both serum cholesterol (especially VLDL) and triglycerides were increased, as has been observed in previous studies of PD patients (30, 32) . The Apo pattern was characterized by decreased levels of ApoA-I and ApoA-II, significantly increased levels of ApoB and ApoC-III, and a decreased C-III ratio, all being characteristic features in renal insufficiency (1) , and furthermore associated with a markedly increased risk of atherosclerotic complications (23, (33) (34) (35) (36) .
An interesting finding of the present study was that the LP-A-I:A-II level seems to decrease with longer duration of PD. The impact of duration of PD on dyslipoproteinemia may be a rather early finding that plays its major role during the first year of treatment. Since the median time of PD treatment in our patients was less than 1 year, the observed association of duration of PD and ApoA-containing lipoproteins is not in conflict with the reports by Sniderman et al. (7) and Wheeler (3) , which state that the changes in lipoprotein metabolism associated with PD appear to occur early during the course of treatment and re- main essentially stable during the following 2 to 3 years. Furthermore, there seems to be a correlation between peritoneal properties (the area parameter) and ApoA-II, implying that the dialysis procedure itself could be of importance in the aggravation of dyslipoproteinemia.
The two specific metabolic characteristics of PD are the continuous loss of protein and other substances of large molecular weight into the dialysate, and a considerable glucose uptake from the dialysis fluid. It is possible, and indirectly supported by some studies (7, 32, 37, 38) , that these features could play an important role in accentuating the hyperlipidemia of PD patients.
Continuous glucose uptake (in this study amounting to 300 -800 kcal/day, corresponding to 75 -200 g glucose) means a nonnegligible addition of calories to these patients. This may further increase the production of triglycerides and thereby the concentration of triglyceride-enriched lipoproteins (30, 32, 38) . However, we did not find any correlation between LP-Bc and calorie uptake in the present study. Our inability to directly connect glucose uptake with triglyceride enrichment of lipoproteins is shared with other reports and may, at least partly, be explained by statistical methodological reasons, since all patients had a generally high range of glucose uptake (4, 29, 31) . Hence, with all patients clustered together at one end of a distribution curve, it may be difficult to detect significant correlations between variables of interest.
Peritoneal losses of protein and other macromolecular solutes, which may include liporegulatory substances, could also affect the concentrations of ApoB-containing lipoproteins, similar to the discussed pathophysiological mechanism of hyperlipidemia in nephrotic syndrome (39) . The underlying pathophysiological mechanism may be local interstitial depletion of albumin during PD. This reduction in the albumin pool and/or losses of liporegulatory substances may trigger the liver to increase protein synthesis, including the synthesis of Apos such as ApoB (40) . Heimbürger et al. found correlations between LDL and Lp(a) and the peritoneal clearances of β 2 -microglobulin and albumin (37) . Similar observations were made by Kagan et al. (4) . However, we did not find any association between total peritoneal protein losses and any of the lipoprotein variables. One possible explanation may be, similar to the lack of correlation between glucose uptake and triglyceriderich lipoproteins, that all patients had substantial protein losses in the dialysate. Hence, this study variable was also at one side of a distribution curve. It is theoretically possible that all the patients lost liporegulatory substances to such a significant extent, and that lipid metabolism was disturbed to a similar degree in all of them.
A decreased metabolism of triglyceride-rich lipoproteins is a major feature in renal failure. It is not established to what degree PD further impairs this abnormality. The accumulation of triglyceride-rich lipoproteins may, at least partly, be a consequence of decreased activity of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL). Theoretically, in PD patients, there could be an accumulation of poorly dialyzable inhibitors of these enzymes, or an increased loss of activators because of the additive peritoneal clearance. An abnormal composition of the ApoB-containing lipoproteins, which provide a less suitable substrate for the enzymatic action of lipolytic enzymes, could also contribute to the accumulation of triglyceride-rich lipoproteins. This altered lipoprotein composition may also result in a reduced cellular uptake (6, 41) . ApoC-III is thought to play a key-role in the enzymatic processes, but the mechanism by which it exerts its effect is still to be determined (42) , as is the primary cause of the increased concentration of ApoC-III.
The relation between LPA-I:A-II and the duration of PD therapy seen in this study indicates that the dialytic procedure itself plays a role in the development of lipoprotein abnormalities. Low concentrations of HDL are considered to be associated with an increased catabolism, or increased losses of HDL rather than a decreased synthesis (43) . HDL, that is, lipoproteins including ApoA-I and ApoA-II, is lost in the dialysate to a greater extent than VLDL/LDL (4, 9, 44, 45) . This could at least to some extent be explained by the smaller size of HDL (4, 44, 45) . In their study, Kagan and co-workers concluded that the chronic peritoneal loss of HDL contributed to the decreased level of HDL (4). Since ApoA-I is an important cofactor of LCAT, a possible consequence of these peritoneal losses may be that the maturation of HDL and the "reverse cholesterol transport" activity become impaired (1) . This could in turn negatively influence atherogenesis (23, (33) (34) (35) (36) .
The PD clearance of LDL is only 40% of the 0.1 mL/ min/1.73 m 2 BSA reported for HDL (4) . Actually, the clearance of HDL is close to that of albumin (46), despite the fact that HDL is larger than albumin and even larger than IgG. Solutes larger than albumin are believed to pass exclusively through their largepore equivalent (47, 48) . However, there are reports suggesting that HDL may also be transported across microvascular endothelium by receptor-operated vesicular transport (49) . If such a mechanism exists in the peritoneal capillary endothelium in patients treated with PD, it could explain why the clearance of HDL is larger than would be expected merely from its molecular size. Furthermore, the number of receptors would be expected to correlate to the effective surface area available for exchange (i.e., the number PDI MAY 2000 -VOL. 20, NO. 3 DYSLIPIDEMIA IN PERITONEAL DIALYSIS of capillaries perfused). This is in accordance with the negative correlation between the area parameter and the serum concentration of ApoA-II found in the present study. In the study by Robinson and Wagner, both LDL and VLDL were less readily incorporated in the endothelial vesicles (49) . As to these solutes, the largepore pathway may be more dominating than for HDL.
In conclusion, the present study confirmed that PD treatment is associated with pronounced, potentially atherogenic, alterations in the lipoprotein pattern. Our data indicate that, with longer duration of PD treatment, dyslipoproteinemia may be aggravated. Furthermore, the inverse relationship between "area" and ApoA-containing lipoproteins indicates that socalled "high transporters" may have a more proatherogenic lipid profile.
However, our findings still do not allow us to identify exactly which factors are the primary participants in the development of the renal dyslipoproteinemia of PD patients. Prospective studies taking into account lipid and lipoprotein levels before dialysis are needed to further elucidate to what degree, and by which mechanisms, PD treatment itself worsens the lipoprotein pattern in these patients. Further studies are also required to examine whether modifications of the PD procedure could diminish these abnormalities, and finally, if lipid-lowering drugs may be able to reduce the incidence of atherosclerotic manifestations in these patients. 
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